Research & Development
Kedrion to be honoured at Premier's Supplier Innovation Celebration
7 October 2026 - Plasma-derived therapies company Kedrion Biopharma announced on Tuesday that it will be honoured by Premier Inc, a technology-driven healthcare improvement company, during the annual ...
Enliven Therapeutics reaches FDA alignment on relcobatinib (ELVN-001) Phase 3 trial design for previously treated CML
7 October 2026 - Enliven Therapeutics Inc (Nasdaq:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced on Tuesday that i...
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
6 October 2026 - India-based pharmaceutical companies Zydus Lifesciences Limited and MSN Laboratories Private Limited announced on Monday the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg an...
FDA approves second Reykjavik manufacturing suite for AVT02
5 October 2026 - Global biotechnology company Alvotech (NASDAQ: ALVO; STO: ALVO-SDB), which develops and manufactures biosimilar medicines, said on Monday it has received US Food and Drug Administrati...
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
5 October 2026 - Ractigen Therapeutics, a China-based, clinical-stage biotechnology company, announced on Saturday the presentation of positive first-in-human clinical data from its ongoing Phase I tr...
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA
5 October 2026 - AnnJi Pharmaceutical Co Ltd (TPEx:7754), a Taiwan-based, clinical-stage drug development company focused on innovative small molecules, announced on Monday that it is proceeding with ...